M120 Risk Score Improves Identification of Children at High Risk of Developing Clinical Type 1 Diabetes and Reports Short-term Response to Preventive Immunotherapy
Authors' conclusion
M120 improves risk stratification and identifies early effects of immunotherapy. It could be applied to increase prevention trial efficiency and guide treatment decisions in the clinic.
Study context
- Population
- TrialNet participants with multiple islet autoantibodies and those who joined the teplizumab prevention trial
- Comparison
- M120 risk score vs OGTT for risk stratification; teplizumab vs placebo for M120 change
- Outcome
- Identification of children at high risk of progression, M120 vs OGTT
Methodological detailssecondary analysis of TrialNet data and the teplizumab prevention trial
- Secondary analysis of TrialNet data and the teplizumab prevention trial
Performance
As reported in the abstract
M120 identified more children at high risk of progression than OGTT
26% more
Further findings
| Outcome | P value |
|---|---|
| Change in M120 in the teplizumab trial · 6 monthsSignificant treatment effect | P < 0.001 |
- Change in M120 in the teplizumab trial — M120 improved after teplizumab
- P = 0.0362
- Change in M120 in the teplizumab trial — M120 deteriorated after placebo
- P = 0.0489
Original publication
M120 Risk Score Improves Identification of Children at High Risk of Developing Clinical Type 1 Diabetes and Reports Short-term Response to Preventive Immunotherapy. Diabetes Care. Published 10 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →